SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-17-148107
Filing Date
2017-04-28
Accepted
2017-04-28 16:05:56
Documents
8
Effectiveness Date
2017-04-28

Document Format Files

Seq Description Document Type Size
1 DEFA14A d307597ddefa14a.htm DEFA14A 36062
2 GRAPHIC g307597pcpg1a.jpg GRAPHIC 5887
3 GRAPHIC g307597pcpg1b.jpg GRAPHIC 3743
4 GRAPHIC g307597pcpg1c.jpg GRAPHIC 2214
5 GRAPHIC g307597pcpg2a.jpg GRAPHIC 3680
6 GRAPHIC g307597pcpg2b.jpg GRAPHIC 2206
7 GRAPHIC g307597pcpg3.jpg GRAPHIC 2212
8 GRAPHIC g307597pcpg4.jpg GRAPHIC 2211
  Complete submission text file 0001193125-17-148107.txt   68440
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36276 | Film No.: 17795425
SIC: 2834 Pharmaceutical Preparations